BIOMAT Database Logo BIOMAT Database Logo

An evaluation of matrix metalloproteinase-9 (Mmp-9) and tissue inhibitor metalloproteinase-1 (Timp-1) Serum levels and the Mmp-9/Timp-1 Ratio in Covid-19 patients. 2023

Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Selcuk University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology 42250 Konya, Turkey.

The progression of COVID-19 has different clinical presentations, which raises a number of immunological questions. This study aimed to investigate MMP-9 and TIMP-1 levels in patients diagnosed with COVID-19 and whether the MMP-9/TIMP-1 ratio is associated with lung involvement in COVID-19. This study was conducted with 192 patients and 45 healthy controls. ELISA was used to measure the MMP-9 and TIMP-1. The MMP-9 and TIMP-1 levels of the patients were found to be higher than those of the controls. MMP-9 and TIMP-1 were detected more in patients with lung involvement on chest CT scans than in those with no lung involvement on chest CT scans. A comparison of lung involvement levels revealed no difference was found between the groups. The MMP-9/TIMP-1 ratio was 5.8 in the group with lung involvement on chest CT scans and 6.1 in the group without lung involvement on chest CT scans. No difference was found between the two groups. A comparison with respect to lung involvement levels showed that the MMP-9/TIMP-1 ratio difference was found between the groups. Diagnostic and treatment methods targeting MMP-9 activity or neutrophil activation may be important in predicting lung involvement in COVID-19 and directing clinical outcomes.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D014057 Tomography, X-Ray Computed Tomography using x-ray transmission and a computer algorithm to reconstruct the image. CAT Scan, X-Ray,CT Scan, X-Ray,Cine-CT,Computerized Tomography, X-Ray,Electron Beam Computed Tomography,Tomodensitometry,Tomography, Transmission Computed,X-Ray Tomography, Computed,CAT Scan, X Ray,CT X Ray,Computed Tomography, X-Ray,Computed X Ray Tomography,Computerized Tomography, X Ray,Electron Beam Tomography,Tomography, X Ray Computed,Tomography, X-Ray Computer Assisted,Tomography, X-Ray Computerized,Tomography, X-Ray Computerized Axial,Tomography, Xray Computed,X Ray Computerized Tomography,X Ray Tomography, Computed,X-Ray Computer Assisted Tomography,X-Ray Computerized Axial Tomography,Beam Tomography, Electron,CAT Scans, X-Ray,CT Scan, X Ray,CT Scans, X-Ray,CT X Rays,Cine CT,Computed Tomography, Transmission,Computed Tomography, X Ray,Computed Tomography, Xray,Computed X-Ray Tomography,Scan, X-Ray CAT,Scan, X-Ray CT,Scans, X-Ray CAT,Scans, X-Ray CT,Tomographies, Computed X-Ray,Tomography, Computed X-Ray,Tomography, Electron Beam,Tomography, X Ray Computer Assisted,Tomography, X Ray Computerized,Tomography, X Ray Computerized Axial,Transmission Computed Tomography,X Ray Computer Assisted Tomography,X Ray Computerized Axial Tomography,X Ray, CT,X Rays, CT,X-Ray CAT Scan,X-Ray CAT Scans,X-Ray CT Scan,X-Ray CT Scans,X-Ray Computed Tomography,X-Ray Computerized Tomography,Xray Computed Tomography
D019715 Tissue Inhibitor of Metalloproteinase-1 A member of the family of TISSUE INHIBITOR OF METALLOPROTEINASES. It is a N-glycosylated protein, molecular weight 28 kD, produced by a vast range of cell types and found in a variety of tissues and body fluids. It has been shown to suppress metastasis and inhibit tumor invasion in vitro. TIMP-1,Metalloproteinase-1 Tissue Inhibitor,Tissue Inhibitor of Metalloproteinase 1
D020780 Matrix Metalloproteinase 9 An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V. Gelatinase B,92-kDa Gelatinase,92-kDa Type IV Collagenase,MMP-9 Metalloproteinase,MMP9 Metalloproteinase,Matrix Metalloproteinase-9,92 kDa Gelatinase,92 kDa Type IV Collagenase,MMP 9 Metalloproteinase,Metalloproteinase 9, Matrix,Metalloproteinase, MMP-9,Metalloproteinase, MMP9

Related Publications

Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
January 2009, Clinical chemistry and laboratory medicine,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Misuse of serum matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 as a biomarker in multiple sclerosis.
February 2006, Multiple sclerosis (Houndmills, Basingstoke, England),
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
January 2016, Human antibodies,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
March 2006, Journal of neuroimmunology,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
January 2007, Journal of nephrology,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
[Assessment of serum MMP-9, TIMP-1 levels and MMP-9/TIMP-1 ratio in migraine patients with and without aura].
September 2022, Ideggyogyaszati szemle,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
February 2006, Clinical neurology and neurosurgery,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
The Effect of Thiamine, Ascorbic Acid, and the Combination of Them on the Levels of Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitor of Matrix Metalloproteinase-1 (TIMP-1) in Sepsis Patients.
January 2022, Infection and drug resistance,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.
June 2011, International urology and nephrology,
Nazlim Aktug Demir, and Sema Yilmaz Kirik, and Sua Sumer, and Onur Ural, and Hatice Esranur Kiratlı, and Husamettin Vatansev, and Esra Paydas Hayatsal, and Ugur Arslan, and Hakan Cebeci, and Lutfi Saltuk Demir
Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
September 2008, Pediatric hematology and oncology,
Copied contents to your clipboard!